M710 (aflibercept)

M710 Approval Pending

M710 (aflibercept)

M710 Approval Pending

U.S. License Holder:

Mylan

Date of License:

aBLA submitted to FDA October-2021

Last Update:

Nov-15-2023

approved_indications FDA-Approved Indications

M710 (aflibercept) is not FDA-approved. An aBLA has been submitted to the FDA.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.

Yesafili® (Biocon) (September-2023 in the EU; November-2023 in the UK)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2021-00880

U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)

Patent Owner
Regeneron Pharmaceuticals, Inc.

Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson

§ 102 Challenge
Y: Claims 1, 8-12

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y: Claims 1, 8-12

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
23-1395

IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending

IPR2021-00881

U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)

Patent Owner
Regeneron Pharmaceuticals, Inc.

Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson

§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)

IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending

IPR2022-01225

U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)

Patent Owner
Regeneron Pharmaceuticals, Inc.

Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC

§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

IPR Status
Instituted, Pending

IPR2022-01226

U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)

Patent Owner
Regeneron Pharmaceuticals, Inc.

Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC

§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

IPR Status
Instituted, Pending

IPR2023-00099

U.S. Patent No.
10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)

Patent Owner
Regeneron Pharmaceuticals, Inc.

Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC

§ 102 Challenge
Y: Claims 1-3

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claims 1-3

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims Prior to Institution Decision)

IPR Status
IPR Not Instituted Due to Disclaimer

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:22-cv-00061 (N.D.W.Va.)

U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,406,226 (Method of Manufacturing VEGF Antagonist Fusion Proteins) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 10,973,879 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,186,625 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,332,771 (Serum-Free Cell Culture Medium)

Plaintiffs
Regeneron Pharmaceuticals, Inc.

Defendants
Mylan Pharmaceuticals Inc.; Biocon Biologics Inc.; Amgen USA, Inc. (Intervenor)

Status
Case Ongoing

BPCIA
Y

Related News

BPCIA Litigation Related to Proposed Eylea Biosimilar CT-P42 Filed
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
November 22, 2023
Spotlight On: Biosimilar Litigations
April Breyer Menon Ha Kung Wong
October 31, 2023
Venable’s BiologicsHQ Monthly Injection – August 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 8, 2022

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha